Pattern of Prostate Specific Antigen and Gleason Score in Relation to Imunohistochemistry Features in Prostate Adenocarcinoma Patients in Dr. Hasan Sadikin General Hospital

Abstract

Objective: To review the correlation between prostate specific antigen (PSA) and Gleason score and Cav-1 for diagnosing prostate adenocarcinoma. Methods: Data were collected from one hundred fifty-nine patients with prostate adenocarcinoma at the Department of Urology, Dr. Hasan Sadikin General Hospital in the period of January 2008-December 2010. The PSA levels were measured and classified into <4 ng/ml, 4-10 ng/ml, and >10 ng/ ml. The results were then analyzed and compared to the imunohistochemistry (caveolin-1) staining in the literature. The Gleason score was also noted and analyzed. Results: This study confirmed that positive caveolin-1 expression was related to the clinical markers of disease progression and was predictive of poor clinical outcome after surgery. The PSA results showed that one hundred fourty-one adenocarcinoma patients had a PSA level of >10 ng/ml with Gleason score of gleason 5-6 as the most common score. However, there was no correlation between PSA and Gleason score and caveolin-1 for diagnosing prostate adenocarcinoma. Conclusions: Caveolin-1 cannot be used to measure Gleason and PSA score due to different markers that have various advantages and disadvantages to predict carcinoma prostate. Therefore, further studies are needed.

Untitled

“…Yarney et al [21] also stated that more (poorly differentiated) lethal tumor stage is likely to produce less PSA serum. Our results share similar sentiments with Glady et al [12] as no statistical association between serum PSA and tumour grade has been identified ( Table 2, p-value = 0.539). This agreed, however, with the statement that poorly differentiated adenocarcinoma results in less PSA serum than adequately differentiated adenocarcinomas ( Table 2).…”

“…Serum PSA has been suggested to produce 70% false positives, rendering it an ineffective method for diagnosing prostate cancer [20]. According to Glady et al, [12], serum PSA has limitations which questioned its efficacy. Their report had it that serum PSA did not reliably predict tumour grade at metastatic stage.…”

Patterns and Presentation of Prostate Cancer in the Brong Ahafo Region of Ghana: A 6-Year Single Center Retrospective Study

“…This can be attributed to different factors such as efficient public health programmes on prostate cancer ensuring that patients visit the health center regularly for screening and the accuracy in the diagnosis from our facility. The use of serum PSA has also increased the prevalence rate in most countries [10]. There has been a decrease in prevalence rate to 31.12% in Asia [11] whiles the opposite has been recorded in the Arab world [12].…”

“…It has been suggested that serum PSA churns out 70% false positives, making it an unreliable tool for diagnosing prostate cancer [18]. According to Glady et al, [10], serum PSA has limitations which questioned its efficacy. In their assertion, they postulated that serum PSA does not reliably predict tumour grade of stage of metastasis.…”

Pattern and Presentation of Prostate Cancer at a Referral Centre in the Brong Ahafo Region of Ghana; A 10-Year Retrospective Study

“…The use of serum PSA in most countries has also raised increased detection rate and concomitant increased prevalence rate [11,12]. Some literature findings show that the prevalence rate in Asia has decreased to 31.12% [13], while in the Arab world the opposite has been reported [14].…”